gadolinium has been researched along with optimark in 31 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (16.13) | 18.2507 |
| 2000's | 16 (51.61) | 29.6817 |
| 2010's | 8 (25.81) | 24.3611 |
| 2020's | 2 (6.45) | 2.80 |
| Authors | Studies |
|---|---|
| Ethier, R; Grossman, R; Kuhn, MJ; Lee, D; Maravilla, K; Olukotun, AY; Reiser, M; Schild, H; Yuh, WT | 1 |
| Rozenberg, D; Terk, MR | 1 |
| Celik, A; Lin, W; Paczynski, RP | 1 |
| Baker, JF; Barr, R; Barr, W; Barron, B; Free, R; Gazelle, GS; Lambrecht, LJ; Maravilla, KR; Pierro, JA; Seltzer, S; Stevens, GR; Swan, SK; Tucker, RM | 1 |
| Adzamli, K; Koenig, SH; Periasamy, MP; Spiller, M | 1 |
| Brunberg, JA; Grodd, W; Grossman, RI; Haughton, VM; Heindel, W; Hunter, G; Jinkins, JR; Kanal, E; Kristy, RM; Kuhn, MJ; Lee, D; Leeds, N; Maravilla, K; Provenzale, JM; Ramsey, R; Rubin, DL; Simon, J; Stevens, GR; Sze, G; Truwit, C; Tu, R; Wippold, FJ; Zelch, J | 1 |
| Galen, KP; Wible, JH; Wojdyla, JK | 1 |
| Jinkins, JR; Muroff, LR; Runge, VM | 1 |
| Choyke, PL; Knopp, MV | 1 |
| Brock, JM; Buonocore, MH; Ivanovic, M; Katzberg, RW; Ryan, JM | 1 |
| Desai, NK; Runge, VM | 1 |
| Heiken, J; Joe, BN; Kang, HP; Narra, V; Parvin, CA; Scott, MG | 1 |
| Hynes, MR; Wible, JH | 1 |
| Barboriak, DP; Dale, BM; Merkle, EM | 1 |
| Collidge, TA; Mark, PB; Thomson, PC; Traynor, JP | 1 |
| Broome, DR; Kanal, E; Martin, DR; Thomsen, HS | 1 |
| Reilly, RF | 1 |
| Perazella, MA | 1 |
| Frenzel, T; Lengsfeld, P; Pietsch, H; Schirmer, H; Sieber, MA; Siegmund, F; Walter, J; Weinmann, HJ | 1 |
| Endo, K; Takahashi-Taketomi, A; Tsushima, Y | 1 |
| Connell, JL; Magnotti, RA; Marietta, PM | 1 |
| Burden, AD; Edward, M; Jardine, AG; Newton, BB; Quinn, JA | 1 |
| Abu Alfa, AK; Bauer, K; Belknap, SM; Bhatt, K; Bull, C; Cowper, SE; Edwards, BJ; Fisher, MJ; Hammel, JA; Kanal, E; Laumann, AE; McKoy, JM; Miller, FH; Nardone, B; Raisch, DW; Restaino, J; Saddleton, E; Samaras, AT; Thomsen, HS; West, DP | 1 |
| Kay, J; Todd, DJ | 1 |
| AlObaidy, M; Burke, LM; Jay, M; Ramalho, J; Ramalho, M; Semelka, RC; Vakharia, A | 1 |
| Jay, M; Prybylski, JP; Semelka, RC | 1 |
| Runge, VM | 1 |
| Prybylski, JP; Ramalho, M; Semelka, RC | 1 |
| Al Saleh, T; Baalbaki, M; Chehabeddine, L; Hannoun, S; Khoury, SJ; Saleh, E | 1 |
| Davenport, MS; McGrath, TA; McInnes, MDF; Schieda, N; Shankar, T; Walker, DT | 1 |
| Akbas, E; Unal, F; Yuzbasioglu, D | 1 |
5 review(s) available for gadolinium and optimark
| Article | Year |
|---|---|
Central nervous system: review of clinical use of contrast media.
Topics: Central Nervous System Diseases; Contrast Media; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Image Enhancement; Magnetic Resonance Imaging; Organometallic Compounds | 2001 |
Contrast use at low field: a review.
Topics: Brain Neoplasms; Contrast Media; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Joint Diseases; Magnetic Resonance Imaging; Multiple Sclerosis; Organometallic Compounds | 2003 |
Gadolinium-Induced Fibrosis.
Topics: Animals; Contrast Media; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Terminology as Topic | 2016 |
Critical Questions Regarding Gadolinium Deposition in the Brain and Body After Injections of the Gadolinium-Based Contrast Agents, Safety, and Clinical Recommendations in Consideration of the EMA's Pharmacovigilance and Risk Assessment Committee Recommend
Topics: Animals; Bone and Bones; Brain; Contrast Media; Europe; Gadolinium; Gadolinium DTPA; Humans; Injections, Intravenous; Magnetic Resonance Imaging; Marketing; Meglumine; Muscle, Skeletal; Organometallic Compounds; Pharmacovigilance; Practice Guidelines as Topic; Risk Assessment | 2017 |
Breakthrough Hypersensitivity Reactions to Gadolinium-based Contrast Agents and Strategies to Decrease Subsequent Reaction Rates: A Systematic Review and Meta-Analysis.
Topics: Contrast Media; Drug Hypersensitivity; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Organometallic Compounds; Skin Tests | 2020 |
4 trial(s) available for gadolinium and optimark
| Article | Year |
|---|---|
Multicenter evaluation of the safety, tolerance, and efficacy of OptiMARK in magnetic resonance imaging of the brain and spine.
Topics: Adult; Aged; Aged, 80 and over; Brain; Contrast Media; Cross-Over Studies; Double-Blind Method; Female; Gadolinium; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Organometallic Compounds; Spine | 1998 |
Gadolinium-enhanced MR imaging of traumatic hepatic injury.
Topics: Adult; Contrast Media; Double-Blind Method; Female; Gadolinium; Gadolinium DTPA; Humans; Liver; Magnetic Resonance Imaging; Male; Organometallic Compounds; Prospective Studies; Tomography, X-Ray Computed; Wounds, Gunshot; Wounds, Nonpenetrating | 1998 |
Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function.
Topics: Adult; Central Nervous System; Central Nervous System Diseases; Contrast Media; Double-Blind Method; Female; Gadolinium; Humans; Injections, Intravenous; Liver; Liver Diseases; Magnetic Resonance Imaging; Male; Middle Aged; Organometallic Compounds; Renal Insufficiency; Safety | 1999 |
Magnetic resonance imaging in patients with central nervous system pathology: a comparison of OptiMARK (Gd-DTPA-BMEA) and Magnevist (Gd-DTPA).
Topics: Adult; Aged; Brain; Central Nervous System Diseases; Contrast Media; Double-Blind Method; Female; Gadolinium; Gadolinium DTPA; Humans; Male; Middle Aged; Organometallic Compounds; Spinal Cord | 2000 |
22 other study(ies) available for gadolinium and optimark
| Article | Year |
|---|---|
Regional cerebral blood volume: a comparison of the dynamic imaging and the steady state methods.
Topics: Animals; Brain; Cerebrovascular Circulation; Contrast Media; Echo-Planar Imaging; Gadolinium; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Organometallic Compounds; Swine | 1999 |
NMRD assessment of Gd-DTPA-bis(methoxyethylamide), (Gd-DTPA-BMEA), a nonionic MRI agent.
Topics: Contrast Media; Gadolinium; Gadolinium DTPA; Humans; Ligands; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Organometallic Compounds; Pentetic Acid | 1999 |
Cardiovascular effects caused by rapid administration of gadoversetamide injection in anesthetized dogs.
Topics: Anesthesia; Animals; Cardiovascular System; Contrast Media; Dogs; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Injections, Intravenous; Male; Organometallic Compounds; Time Factors | 2001 |
Pseudohypocalcemia with MR imaging contrast agents: a cautionary tale.
Topics: Calcium; Contrast Media; Gadolinium; Gadolinium DTPA; Humans; Hypocalcemia; Injections, Intravenous; Magnetic Resonance Imaging; Organometallic Compounds | 2003 |
Cortical, medullary, and pelvocaliceal MR renography with and without diuretic modification.
Topics: Adult; Case-Control Studies; Contrast Media; Diuretics; Feasibility Studies; Female; Furosemide; Gadolinium; Gadolinium DTPA; Humans; Hydronephrosis; Injections, Intravenous; Kidney; Magnetic Resonance Imaging; Male; Organometallic Compounds | 2003 |
Model for predicting the impact of gadolinium on plasma calcium measured by the o-cresolphthalein method.
Topics: Calcium; Contrast Media; False Positive Reactions; Gadolinium; Gadolinium DTPA; Humans; Indicators and Reagents; Models, Biological; Organometallic Compounds; Phenolphthaleins; Reference Values; Time Factors | 2004 |
Measurement of serum calcium concentration after administration of gadoversetamide in dogs.
Topics: Analysis of Variance; Animals; Calcium; Chelating Agents; Coloring Agents; Contrast Media; Dogs; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Injections, Intravenous; Male; Mass Spectrometry; Organometallic Compounds; Phenolphthaleins; Time Factors | 2004 |
Gain in signal-to-noise for first-pass contrast-enhanced abdominal MR angiography at 3 Tesla over standard 1.5 Tesla: prediction with a computer model.
Topics: Abdomen; Adult; Computer Simulation; Contrast Media; Dose-Response Relationship, Drug; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Image Enhancement; Magnetic Resonance Angiography; Magnetics; Male; Meglumine; Middle Aged; Models, Biological; Organometallic Compounds; Predictive Value of Tests; Signal Processing, Computer-Assisted | 2007 |
Gadolinium contrast may be risky in kidney disease.
Topics: Contrast Media; Fibromyalgia; Gadolinium; Gadolinium DTPA; Humans; Kidney Diseases; Magnetic Resonance Angiography; Organometallic Compounds; Peripheral Vascular Diseases; Risk Factors | 2007 |
Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update.
Topics: Contrast Media; Fibrosis; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds; Renal Insufficiency; Risk; United States; United States Food and Drug Administration | 2008 |
Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis.
Topics: Aged; Contrast Media; Female; Fibrosis; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Hospitals, Veterans; Humans; Kidney Diseases; Kidney Failure, Chronic; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Male; Middle Aged; Organometallic Compounds; Renal Dialysis; Risk Assessment; Skin Diseases; Texas; Time Factors | 2008 |
How should nephrologists approach gadolinium-based contrast imaging in patients with kidney disease?
Topics: Contrast Media; Fibrosis; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Kidney Diseases; Kidney Failure, Chronic; Magnetic Resonance Angiography; Magnetic Resonance Imaging; Organometallic Compounds; Patient Selection; Renal Dialysis; Risk Assessment; Skin Diseases; Time Factors | 2008 |
Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand.
Topics: Animals; Contrast Media; Copper; Fibrosis; Gadolinium; Gadolinium DTPA; Kidney Diseases; Ligands; Male; Organometallic Compounds; Rats; Skin Diseases; Statistics, Nonparametric; Tissue Distribution; Zinc | 2008 |
Nephrogenic systemic fibrosis in Japan: advisability of keeping the administered dose as low as possible.
Topics: Contrast Media; Fibrosis; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds; Renal Insufficiency; Risk; Risk Factors | 2008 |
Automated colorimetric gadolinium assay for verification of clearance and estimation of glomerular filtration rate.
Topics: Animals; Automation; Biological Assay; Cats; Colorimetry; Contrast Media; Gadolinium; Gadolinium DTPA; Glomerular Filtration Rate; Magnetic Resonance Imaging; Mass Spectrometry; Organometallic Compounds; Reproducibility of Results; Sensitivity and Specificity | 2009 |
Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation.
Topics: Adult; Cell Proliferation; Collagen; Contrast Media; Dose-Response Relationship, Drug; Edetic Acid; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Hyaluronic Acid; Linear Models; Magnetic Resonance Imaging; Meglumine; Middle Aged; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds | 2010 |
Advancing pharmacovigilance through academic-legal collaboration: the case of gadolinium-based contrast agents and nephrogenic systemic fibrosis-a Research on Adverse Drug Events and Reports (RADAR) report.
Topics: Contrast Media; Cooperative Behavior; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Male; Meglumine; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Pharmacovigilance; Registries; United States | 2014 |
Gadolinium deposition disease: Initial description of a disease that has been around for a while.
Topics: Adult; Aged; Contrast Media; Female; Gadolinium; Gadolinium DTPA; Heterocyclic Compounds; Humans; Magnetic Resonance Imaging; Male; Meglumine; Middle Aged; Organometallic Compounds; Pain; Prospective Studies | 2016 |
The stability of gadolinium-based contrast agents in human serum: A reanalysis of literature data and association with clinical outcomes.
Topics: Chelating Agents; Chromatography, High Pressure Liquid; Contrast Media; Data Interpretation, Statistical; Drug Stability; Gadolinium; Gadolinium DTPA; Humans; Kinetics; Magnetic Resonance Imaging; Meglumine; Organometallic Compounds; Treatment Outcome | 2017 |
Influence of excess ligand on Nephrogenic Systemic Fibrosis associated with nonionic, linear gadolinium-based contrast agents.
Topics: Adverse Drug Reaction Reporting Systems; Animals; Contrast Media; Databases, Factual; Fibrosis; Gadolinium; Gadolinium DTPA; Humans; Incidence; Kinetics; Ligands; Nephrogenic Fibrosing Dermopathy; Organometallic Compounds; Rats; Retrospective Studies; Skin Diseases; Thermodynamics; United States | 2019 |
Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents.
Topics: Adult; Brain; Cerebellar Nuclei; Contrast Media; Environmental Exposure; Female; Gadolinium; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Male; Meglumine; Organometallic Compounds | 2019 |
Genotoxic effects of gadobutrol and gadoversetamide active substances used in magnetic resonance imaging in human peripheral lymphocytes
Topics: Chromosome Aberrations; Contrast Media; DNA Damage; Gadolinium; Humans; Lymphocytes; Magnetic Resonance Imaging; Micronucleus Tests; Sister Chromatid Exchange | 2022 |